Form 4: Amicus Therapeutics CEO Bradley Campbell Exercises and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Amicus Therapeutics CEO Bradley L. Campbell executed stock options and sold shares on September 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 3, 2024, Bradley L. Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 7,500 shares of common stock at a price of $8.61 per share.
- Simultaneously, Campbell sold 7,500 shares of common stock at a weighted average price of $11.7064, with prices ranging from $11.60 to $11.97.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on August 23, 2023.
- Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock and 22,500 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-arranged trading plan. There's no indication of positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to use Rule 10b5-1 plans to manage their stock holdings and avoid accusations of trading on inside information. The market will likely interpret this as a standard transaction unless the volume or pattern deviates significantly from past behavior.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a form of long-term incentive.
- Rule 10b5-1 trading plans are a common tool used by corporate insiders to manage their stock sales in compliance with securities laws.
- Comparing Campbell's trading activity to that of CEOs at similar-sized biotech companies (e.g., BioMarin, Sarepta) could provide context on the scale and frequency of such transactions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, depending on how the market interprets the insider activity.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| 08/23/2023 | Date of adoption of Rule 10b5-1 trading plan. |
| 09/03/2024 | Date of stock option exercise and sale of shares. |
| 09/05/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.